Vogt-Koyanagi-Harada (VKH) disease is a rare autoimmune condition primarily affecting pigmented tissues, including the eyes, inner ear, skin, and meninges. It is characterized by bilateral granulomatous uveitis, which involves inflammation of the uvea (the middle layer of the eye). Clinically, VKH disease manifests in phases: prodromal (flu-like symptoms), uveitic (blurred vision, eye pain), convalescent (gradual improvement), and chronic/recurrent (possible vision impairment). Ophthalmic signs include exudative retinal detachments, disc swelling, and diffuse choroiditis. The exact cause remains unclear, but it's believed to involve genetic predisposition triggered by viral infections or other environmental factors. Treatment typically involves high-dose corticosteroids to suppress inflammation, often supplemented with immunosuppressive agents like methotrexate or cyclosporine in severe cases. Early intervention is crucial to prevent irreversible vision loss and manage systemic manifestations of the disease effectively.
Introduction: Vogt-Koyanagi-Harada (VKH) disease is rarely observed in preschool-aged children, and when it does occur, it typically presents with exudative retinal detachment during the acute phase.…
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Oral and poster slots for original Vogt-Koyanagi-Harada Disease work, reviewed by the scientific committee.
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Plenary lectures from leading voices shaping Vogt-Koyanagi-Harada Disease research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Vogt-Koyanagi-Harada Disease track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Vogt-Koyanagi-Harada Disease. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Vogt-Koyanagi-Harada Disease are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IOC 2027 is a hybrid conference — attend the Vogt-Koyanagi-Harada Disease track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
